Bosutinib Discount Agreements
Titre original de l'avis
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Bosutinib, ATC L01EA04
Score d'opportunité
Pourquoi ce score ?
Opportunité
40 / 100
Complexité
20 / 100
Facteurs de risque
No guaranteed sales volume; discounts are purely contractual without minimum purchase obligations.
Agreements automatically terminate if a competitive discount agreement for Bosutinib is concluded at national or region...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Nov 2026
- Non-exclusive discount agreements for Bosutinib (ATC L01EA04) pharmaceutical products
- All interested pharmaceutical companies can join
Afficher le résumé complet
The AOK Bayern is conducting an open-house model (not a competitive tender) to enter into non-exclusive discount agreements with all interested pharmaceutical companies for the active substance Bosutinib (ATC L01EA04) under § 130a Abs. 8 SGB V. The contract runs from 01.12.2024 to 30.11.2026, with the possibility of joining any time until 05.10.2026. No estimated value is provided. The procedure is outside procurement law; agreements are identical and non-negotiable. Eligibility is solely demonstrated via a signed self-declaration of reliability.
Risques
No guaranteed sales volume; discounts are purely contractual without minimum purchase obligations.
Agreements automatically terminate if a competitive discount agreement for Bosutinib is concluded at national or region...
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Must be a pharmaceutical company (pharmazeutischer Unternehmer)
Administrative
- Submit signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
- Submit signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel'
Les exigences peuvent être incomplètes.
Critères d'attribution
Lot 1
Acheteur
Localisation
München, DEU
Site web
Profil acheteur
Identifiant
DE811695320
Activité
Health
Lots (1)
LOT-0001
Bosutinib Discount Agreements
Non-exclusive discount agreements for pharmaceutical products containing Bosutinib (ATC L01EA04). All interested pharmaceutical companies meeting eligibility can join. Contracts identical, not negotiable. Early start 01.12.2024, end 30.11.2026.
Localisation
Durée
Catégorie
Critères d'attribution
Date limite
Détails des critères
No award criteria
this is an open-house model with no selection decision.
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Open house Arzneimittelrabattverträge Bosutinib, ATC L01EA04
Description TED originale
Siehe kurze Beschreibung
Détails de la procédure
- Date de publication
- 16 Oct 2024
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 628220-2024
Documents (2)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
40 / 100
Complexité
20 / 100
Facteurs de risque
No guaranteed sales volume; discounts are purely contractual without minimum purchase obligations.
Agreements automatically terminate if a competitive discount agreement for Bosutinib is concluded at national or region...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications